Actively Recruiting
Randomized, Double-Blind Study Evaluating Spesolimab Infusions for Treating Ulcerative Pyoderma Gangrenosum in Adults
Led by LEO Pharma · Updated on 2026-10-23
90
Participants Needed
104
Research Sites
40 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether spesolimab helps adults with ulcerative pyoderma gangrenosum PG, a skin condition causing ulcers. The study focuses on whether spesolimab leads to the closure of PG ulcers and compares this with a placebo. This phase 3 clinical trial is randomized, double-blind, and placebo-controlled, enrolling adults with at least one ulcer between 5 cm and 80 cm in size. Participants are randomly assigned to receive either spesolimab or a placebo infusion every 4 weeks. In the first part of the study, all participants also take corticosteroid medicine by mouth for 8 weeks. In the second part, those without open ulcers are again randomly assigned to spesolimab or placebo, while participants with open ulcers receive spesolimab. The study includes two treatment phases to evaluate the effects under different conditions. Participants stay in the trial for about 1.5 years, attending around 20 study visits. During visits, doctors examine the skin for signs of PG, monitor overall health, and watch for any side effects. The main outcome is the complete closure of the target PG ulcer up to week 26, confirmed at a later visit. Secondary outcomes include pain reduction and quality of life improvements. The study compares results between groups to assess the treatments impact and monitors participants safety throughout.
CONDITIONS
Brief Title
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Research Team
C
Clinical Disclosure
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here